Cargando…

Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis

AIMS: Medical and non-medical switching strategies have been adopted in Europe in the last few years. We aimed to investigate persistence on treatment with a SB5 Adalimumab (SB5) biosimilar after switching from Adalimumab (ADA) originator among patients with inflammatory rheumatic musculoskeletal di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bruni, Cosimo, Gentileschi, Stefano, Pacini, Giovanni, Bardelli, Marco, Tofani, Lorenzo, Bartoli, Francesca, Baldi, Caterina, Cometi, Laura, Fiori, Ginevra, Nacci, Francesca, Cantarini, Luca, Guiducci, Serena, Moggi-Pignone, Alberto, Frediani, Bruno, Matucci-Cerinic, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	The Role of Biosimilars in the Management of Rheumatic Diseases
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804457/ https://www.ncbi.nlm.nih.gov/pubmed/35116080 http://dx.doi.org/10.1177/1759720X211033679

Ejemplares similares

The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases
por: Bruni, Cosimo, et al.
Publicado: (2020)

AVT02: An Adalimumab Biosimilar
por: Kang, Connie
Publicado: (2022)

Risk of Malignancy and Biologic Therapy in Rheumatic Inflammatory Diseases: A Single-center Experience
por: Cometi, Laura, et al.
Publicado: (2020)

Baricitinib in the treatment of rheumatoid arthritis: clinical and ultrasound evaluation of a real-life single-centre experience
por: Tesei, Giulia, et al.
Publicado: (2021)

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
por: Zhao, Sizheng, et al.
Publicado: (2018)

Effect of Dysmetabolisms and Comorbidities on the Efficacy and Safety of Biological Therapy in Chronic Inflammatory Joint Diseases
por: Cometi, Laura, et al.
Publicado: (2020)

GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2017)

SB8: A Bevacizumab Biosimilar
por: Syed, Yahiya Y.
Publicado: (2020)

Role of Adalimumab Biosimilar in the Treatment of Non-Anterior Uveitis Associated with Behçet’s Syndrome
por: Sota, Jurgen, et al.
Publicado: (2021)

PF-06438179/GP1111: An Infliximab Biosimilar
por: Al-Salama, Zaina T.
Publicado: (2018)

MYL-1402O: A Bevacizumab Biosimilar
por: Lee, Arnold
Publicado: (2021)

Combination of denosumab and biologic DMARDs in inflammatory muscle-skeletal diseases and connective tissue diseases
por: Bruni, Cosimo, et al.
Publicado: (2022)

Combination of denosumab and biologic DMARDs in inflammatory muscle-skeletal diseases and connective tissue diseases
por: Bruni, Cosimo, et al.
Publicado: (2022)

The positive side of the coin: Sars-Cov-2 pandemic has taught us how much Telemedicine is useful as standard of care procedure in real life
por: El Aoufy, Khadija, et al.
Publicado: (2021)

Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician
por: Moots, Robert, et al.
Publicado: (2017)

The effectiveness and safety of infliximab compared with biosimilar CT‐P13, in 3112 patients with ulcerative colitis
por: Meyer, Antoine, et al.
Publicado: (2019)

Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
por: Chadwick, Laura, et al.
Publicado: (2018)

Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review
por: Campochiaro, Corrado, et al.
Publicado: (2022)

Polymyalgia rheumatica following infective triggers or vaccinations: a different subset of disease?
por: Falsetti, Paolo, et al.
Publicado: (2020)

Population pharmacokinetics of subcutaneous infliximab CT‐P13 in Crohn’s disease and ulcerative colitis
por: Hanzel, Jurij, et al.
Publicado: (2021)

Bone-sparing effects of rituximab and body composition analysis in a cohort of postmenopausal women affected by rheumatoid arthritis – retrospective study
por: Al Khayyat, Suhel Gabriele, et al.
Publicado: (2021)

Low muscle mass and body composition analysis in a group of postmenopausal women affected by primary Sjögren’s syndrome
por: Al Khayyat, Suhel Gabriele, et al.
Publicado: (2021)

Oral Lactobacillus Species in Systemic Sclerosis
por: Melchiorre, Daniela, et al.
Publicado: (2021)

Difference in pain and accuracy of two hyaluronic acid injection techniques for symptomatic knee osteoarthritis in overweight patients
por: D’Alessandro, Roberto, et al.
Publicado: (2021)

Ultrasound evaluation of the scapholunate ligament and scapholunate joint space in patients with wrist complaints in a rheumatologic setting
por: Falsetti, Paolo, et al.
Publicado: (2021)

Effects of antiresorptive agents on body composition: a case-control retrospective study
por: Al Khayyat, Suhel Gabriele, et al.
Publicado: (2023)

The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis
por: Conticini, Edoardo, et al.
Publicado: (2020)

The Contribution of Imaging Beyond Clinical Diagnosis, the Ochronosis and Synovio-entheseal Complex Examples
por: Pacini, Giovanni, et al.
Publicado: (2022)

Routine IgG4 staining in minor salivary gland biopsy in a cohort of Italian Caucasian patients suffering from xerostomia
por: Conticini, Edoardo, et al.
Publicado: (2022)

Acute and Chronic Complications of Rheumatic Heart Disease
por: McLeod, Peter, et al.
Publicado: (2020)

Rheumatic Disease Disclosure at the Early Career Phase and Its Impact on the Relationship Between Workplace Supports and Presenteeism
por: Jetha, Arif, et al.
Publicado: (2022)

Neridronate for transient osteoporosis of the hip in a child
por: Gaggiano, C., et al.
Publicado: (2022)

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
por: Jiang, Yijia, et al.
Publicado: (2023)

Real‐life Tolerability and Effectiveness of Adalimumab Biosimilar in Ankylosing Spondylitis: the Adalimumab Biosimilar Patient Registry Data
por: Kapoor, Sanjiv, et al.
Publicado: (2019)

The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune‐Mediated Inflammatory Disease
por: Müller-Ladner, Ulf, et al.
Publicado: (2023)

Baricitinib retention rate: ‘real-life’ data from a mono-centric cohort of patients affected by rheumatoid arthritis
por: Baldi, Caterina, et al.
Publicado: (2023)

Genes, autoimmunity and pathogenesis of rheumatic heart disease
por: Guilherme, L, et al.
Publicado: (2011)

Global research priorities in rheumatic fever and rheumatic heart disease
por: Carapetis, Jonathan R, et al.
Publicado: (2011)

Correction to: AVT02: An Adalimumab Biosimilar
por: Kang, Connie
Publicado: (2022)

Navigating adalimumab biosimilars: an expert opinion
por: Abitbol, Vered, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f8llkpk9siufd6r0viffcsjhe2